Rimonabant, known commercially as Acomplia or Redufast, is a drug used for weight loss, whose action on the central nervous system decreases appetite.
This drug works by blocking receptors in the brain and peripheral organs, decreasing hyperactivity of the endocannabinoid system, resulting in decreased appetite, regulation of body weight and energy balance, as well as metabolism of sugar and fats, which helps to lose weight.
- Despite their effectiveness.
- The sale of these drugs has been discontinued due to the increased risk of developing psychiatric complications.
The use of rimonabant is 1 tablet of 20 mg a day, in the morning before breakfast, orally, ingested whole, without breaking or chewing.Treatment should be accompanied by a low-calorie diet and increased physical activity.
The recommended dose of 20 mg per day should not be exceeded due to the increased risk of adverse events.
Rimonabant is an antagonist of cannabinoid receptors and works by blocking a specific type of cannabinoid receptors called CB1, which are found in the nervous system and are part of the system that the body uses to control food intake.These receptors are also present in fat cells., which are adipose tissue cells.
Side effects that may be caused by this medicine include nausea and upper respiratory tract infections, upset stomach, vomiting, sleep disorders, nervousness, depression, irritability, dizziness, diarrhea, anxiety, itching, excessive sweating, muscle cramps or spasms., Fatigue, blackheads, tendon pain and inflammation, memory loss, back pain, impaired hand and foot sensitivity, hot flashes, , drowsiness, night sweats, hiccups, anger.
In addition, symptoms of panic, agitation, emotional disorder, suicidal thoughts, aggression, or aggressive behavior may also occur.
Currently, ribonabant is contracted in the general population, having been withdrawn from the market for its side effects.
At the time of marketing, it was not recommended for use in pregnant women, during lactation, in children under 18 years of age, people with hepatic or renal impairment or with an uncontrolled psychiatric disorder.